Enterprise Value

-139.8M

Cash

501.5M

Avg Qtr Burn

N/A

Short % of Float

6.29%

Insider Ownership

3.97%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HETLIOZ® (tasimelteon) Details
SMS (Smith-Magenis Syndrome)

Approved

Quarterly sales

Fanapt® (iloperidone) Details
Schizophrenia and PDP (Parkinson's disease psychosis)

Approved

Quarterly sales

HETLIOZ® (tasimelteon) Details
Non-24-Hour Sleep-Wake Disorder (Non-24)

Approved

Quarterly sales

Fanapt® (iloperidone) Details
Mental health, Bipolar depression, Bipolar disease

sNDA

Submission

NDA

Submission

NDA

FDA meeting

Tradipitant Details
Pruritus in Atopic Dermatitis | EPIONE

Phase 3

Update

Tradipitant Details
Motion sickness

Phase 3

Update

Phase 2

Data readout

Trichostatin A (VTR-297) Details
Leukemia, Multiple myeloma, Lymphoma

Phase 1

Update

Failed

Discontinued